BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 23565664)

  • 1. Decreased expression of RNA-binding motif protein 3 correlates with tumour progression and poor prognosis in urothelial bladder cancer.
    Boman K; Segersten U; Ahlgren G; Eberhard J; Uhlén M; Jirström K; Malmström PU
    BMC Urol; 2013 Apr; 13():17. PubMed ID: 23565664
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High MCM3 expression is an independent biomarker of poor prognosis and correlates with reduced RBM3 expression in a prospective cohort of malignant melanoma.
    Nodin B; Fridberg M; Jonsson L; Bergman J; Uhlén M; Jirström K
    Diagn Pathol; 2012 Jul; 7():82. PubMed ID: 22805320
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Low RBM3 protein expression correlates with tumour progression and poor prognosis in malignant melanoma: an analysis of 215 cases from the Malmö Diet and Cancer Study.
    Jonsson L; Bergman J; Nodin B; Manjer J; Pontén F; Uhlén M; Jirström K
    J Transl Med; 2011 Jul; 9():114. PubMed ID: 21777469
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Podocalyxin-like and RNA-binding motif protein 3 are prognostic biomarkers in urothelial bladder cancer: a validatory study.
    Boman K; Andersson G; Wennersten C; Nodin B; Ahlgren G; Jirström K
    Biomark Res; 2017; 5():10. PubMed ID: 28293425
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Loss of aquaporin 3 protein expression constitutes an independent prognostic factor for progression-free survival: an immunohistochemical study on stage pT1 urothelial bladder cancer.
    Otto W; Rubenwolf PC; Burger M; Fritsche HM; Rößler W; May M; Hartmann A; Hofstädter F; Wieland WF; Denzinger S
    BMC Cancer; 2012 Oct; 12():459. PubMed ID: 23043286
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pre-clinical and clinical studies on the role of RBM3 in muscle-invasive bladder cancer: longitudinal expression, transcriptome-level effects and modulation of chemosensitivity.
    Wahlin S; Boman K; Moran B; Nodin B; Gallagher WM; Karnevi E; Jirström K
    BMC Cancer; 2022 Feb; 22(1):131. PubMed ID: 35109796
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Low RBM3 protein expression correlates with clinical stage, prognostic classification and increased risk of treatment failure in testicular non-seminomatous germ cell cancer.
    Olofsson SE; Nodin B; Gaber A; Eberhard J; Uhlén M; Jirström K; Jerkeman M
    PLoS One; 2015; 10(3):e0121300. PubMed ID: 25811459
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reduced expression of ezrin in urothelial bladder cancer signifies more advanced tumours and an impaired survival: validatory study of two independent patient cohorts.
    Andersson G; Wennersten C; Gaber A; Boman K; Nodin B; Uhlén M; Segersten U; Malmström PU; Jirström K
    BMC Urol; 2014 May; 14():36. PubMed ID: 24885195
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Membranous expression of podocalyxin-like protein is an independent factor of poor prognosis in urothelial bladder cancer.
    Boman K; Larsson AH; Segersten U; Kuteeva E; Johannesson H; Nodin B; Eberhard J; Uhlén M; Malmström PU; Jirström K
    Br J Cancer; 2013 Jun; 108(11):2321-8. PubMed ID: 23652315
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High RBM3 expression is associated with an improved survival and oxaliplatin response in patients with metastatic colorectal cancer.
    Siesing C; Sorbye H; Dragomir A; Pfeiffer P; Qvortrup C; Pontén F; Jirström K; Glimelius B; Eberhard J
    PLoS One; 2017; 12(8):e0182512. PubMed ID: 28800641
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High RNA-Binding Motif Protein 3 (RBM3) Expression is Independently Associated with Prolonged Overall Survival in Intestinal-Type Gastric Cancer.
    Ye F; Jin P; Cai X; Cai P; Cai H
    Med Sci Monit; 2017 Dec; 23():6033-6041. PubMed ID: 29263314
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Incident urothelial cancer in the Malmö Diet and Cancer Study: cohort characteristics and further validation of ezrin as a prognostic biomarker.
    Wennersten C; Andersson G; Boman K; Nodin B; Gaber A; Jirström K
    Diagn Pathol; 2014 Oct; 9():189. PubMed ID: 25278252
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combination of CK20 and Ki-67 immunostaining analysis predicts recurrence, progression, and cancer-specific survival in pT1 urothelial bladder cancer.
    Bertz S; Otto W; Denzinger S; Wieland WF; Burger M; Stöhr R; Link S; Hofstädter F; Hartmann A
    Eur Urol; 2014 Jan; 65(1):218-26. PubMed ID: 22633802
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bromodomain 4 protein is a predictor of survival for urothelial carcinoma of bladder.
    Yan Y; Yang FQ; Zhang HM; Li J; Li W; Wang GC; Che JP; Zheng JH; Liu M
    Int J Clin Exp Pathol; 2014; 7(7):4231-8. PubMed ID: 25120803
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Loss of lactate dehydrogenase B subunit expression is correlated with tumour progression and independently predicts inferior disease-specific survival in urinary bladder urothelial carcinoma.
    Liao AC; Li CF; Shen KH; Chien LH; Huang HY; Wu TF
    Pathology; 2011 Dec; 43(7):707-12. PubMed ID: 22027740
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ki-67 MIB1 labelling index and the prognosis of primary TaT1 urothelial cell carcinoma of the bladder.
    Quintero A; Alvarez-Kindelan J; Luque RJ; Gonzalez-Campora R; Requena MJ; Montironi R; Lopez-Beltran A
    J Clin Pathol; 2006 Jan; 59(1):83-8. PubMed ID: 16394286
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expression of the RNA-binding protein RBM3 is associated with a favourable prognosis and cisplatin sensitivity in epithelial ovarian cancer.
    Ehlén A; Brennan DJ; Nodin B; O'Connor DP; Eberhard J; Alvarado-Kristensson M; Jeffrey IB; Manjer J; Brändstedt J; Uhlén M; Pontén F; Jirström K
    J Transl Med; 2010 Aug; 8():78. PubMed ID: 20727170
    [TBL] [Abstract][Full Text] [Related]  

  • 18. IMP3 is a biomarker for non-muscle-invasive urothelial carcinoma of the bladder associated with an aggressive phenotype.
    Yang F; Zhou Q; Meng L; Xing N
    Medicine (Baltimore); 2019 Jul; 98(27):e16009. PubMed ID: 31277094
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CD147 overexpression allows an accurate discrimination of bladder cancer patients' prognosis.
    Afonso J; Longatto-Filho A; Baltazar F; Sousa N; Costa FE; Morais A; Amaro T; Lopes C; Santos LL
    Eur J Surg Oncol; 2011 Sep; 37(9):811-7. PubMed ID: 21733655
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Overexpression of YAP 1 contributes to progressive features and poor prognosis of human urothelial carcinoma of the bladder.
    Liu JY; Li YH; Lin HX; Liao YJ; Mai SJ; Liu ZW; Zhang ZL; Jiang LJ; Zhang JX; Kung HF; Zeng YX; Zhou FJ; Xie D
    BMC Cancer; 2013 Jul; 13():349. PubMed ID: 23870412
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.